Abstract

The proposal is designed to enable continued participation of Hotel Dieu de Montreal and the University of Montreal Hospital Centre as a main member of NSABP. Hotel Dieu de Montreal has been supported as a main member since 1987 (and has been involved in NSABP activities since 1981). This hospital has been incorporated through a decision of the government of the Province of Quebec, providing three hospitals under a single administration. By formal agreement, Dr. Robidoux will act as the sole Principal Investigator.
The aim of this proposal, by extension from those of NSABP, is to improve disease-free survival and total survival in patients with primary breast and colorectal cancers. Hotel Dieu de Montreal has an excellent record of 0 percent follow-up data delinquency, and is currently following 386 patients on long term adjuvant protocols.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA044066-13
Application #
2654026
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Program Officer
Kaplan, Richard S
Project Start
1987-04-15
Project End
2000-01-31
Budget Start
1998-02-01
Budget End
1999-01-31
Support Year
13
Fiscal Year
1998
Total Cost
Indirect Cost

  Institution

Name
Hotel Dieu de Montreal
Department
Type
DUNS #
City
Montreal
State
PQ
Country
Canada
Zip Code

  Publications

Bear, Harry D; Tang, Gong; Rastogi, Priya et al. (2017) The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. Ann Surg Oncol 24:1853-1860
Jatoi, Ismail; Bandos, Hanna; Jeong, Jong-Hyeon et al. (2016) Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy. J Natl Cancer Inst 108:
Wickerham, D Lawrence; Vogel, Victor G (2015) Breast cancer chemoprevention: the saga of underuse continues. J Natl Cancer Inst 107:399
Bear, Harry D; Tang, Gong; Rastogi, Priya et al. (2015) Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol 16:1037-1048
Swain, Sandra M; Tang, Gong; Geyer Jr, Charles E et al. (2013) Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol 31:3197-204
Bear, Harry D; Tang, Gong; Rastogi, Priya et al. (2012) Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 366:310-20
Paterson, Alexander H G; Anderson, Stewart J; Lembersky, Barry C et al. (2012) Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 13:734-42
Krag, David N; Anderson, Stewart J; Julian, Thomas B et al. (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927-33